SVRA logo

SVRA
Savara Inc

22,707
Mkt Cap
$1.3B
Volume
4.02M
52W High
$6.61
52W Low
$1.89
PE Ratio
-12.15
SVRA Fundamentals
Price
$6.50
Prev Close
$6.37
Open
$6.44
50D MA
$4.30
Beta
1.01
Avg. Volume
2.12M
EPS (Annual)
-$0.4838
P/B
11.90
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Savara (NASDAQ:SVRA) Shares Up 6.8% - What's Next?
Savara (NASDAQ:SVRA) Trading 6.8% Higher - What's Next...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Savara (NASDAQ:SVRA) Shares Gap Down - Here's Why
Savara (NASDAQ:SVRA) Shares Gap Down - Time to Sell...
MarketBeat·4d ago
News Placeholder
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow Nebulizer System
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has issued patent No. 4 496 611...
Business Wire·4d ago
News Placeholder
F m Investments LLC Acquires 91,830 Shares of Savara Inc. $SVRA
F m Investments LLC boosted its holdings in shares of Savara Inc. (NASDAQ:SVRA - Free Report) by 41.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·5d ago
News Placeholder
Savara (NASDAQ:SVRA) Sees Strong Trading Volume - Here's Why
Savara (NASDAQ:SVRA) Sees Large Volume Increase - Should You Buy...
MarketBeat·7d ago
News Placeholder
Savara (NASDAQ:SVRA) Hits New 12-Month High - Here's What Happened
Savara (NASDAQ:SVRA) Sets New 12-Month High - Time to Buy...
MarketBeat·9d ago
News Placeholder
Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the stock, MarketBeat Ratings reports. One...
MarketBeat·14d ago
News Placeholder
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host one on one meetings...
Business Wire·15d ago
News Placeholder
Savara (NASDAQ:SVRA) Shares Up 7.3% - Still a Buy?
Savara (NASDAQ:SVRA) Stock Price Up 7.3% - Still a Buy...
MarketBeat·16d ago
News Placeholder
HC Wainwright Has Positive Outlook of Savara FY2029 Earnings
Savara Inc. (NASDAQ:SVRA - Free Report) - Stock analysts at HC Wainwright increased their FY2029 earnings per share estimates for Savara in a research note issued on Thursday, November 13th. HC...
MarketBeat·18d ago

Latest SVRA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.